Is risankizumab better than secukinumab in the treatment of plaque psoriasis?

Abstract

Plaque psoriasis is a common inflammatory disease that causes raised, flaky plaques or patches on the skin. An abnormal immune system can be an important cause of psoriasis. Risankizumab and secukinumab are biologic drugs that are injected under a patient’s skin to treat different parts of the immune system. Both drugs are approved in the U. S. and E. U. to treat moderate‐to‐severe plaque psoriasis.